Basket | Login


Project Structure

PharmaCog's Scientific Approach

Pharmacog Logo

This approach is fundamentally dependant on a mutual understanding and effective scientific exchanges between pre-clinical and clinical scientists. In order to achieve this, research activities have been separated into 3 main Blocks each of which have both a pre-clinical and clinical workpackage within them.

  • Block 1 (WP1&2) : Development and validation of translatable pharmacodynamic models of cognitive impairment (HVT models)
  • Block 2 (WP3&4) : Development and validation of translatable pharmacodynamic markers for symptomatic agents
  • Block 3 (WP5&6) : Development of translatable biomarkers for disease-modifying drugs and identification of animal models with increased predictive capacity

These research blocks are supported by WP7 which is dedicated to the pharmacokinetic assessment (measurement of drug levels) and mathematical modelling of the data generated to maximise our understanding of the data and optimise future study designs. Similarly an experienced group of statisticians (WP8) will work alongside both pre-clinical and clinical researchers to ensure that all study designs and data analysis methods are fully optimised. Furthermore this group will ensure that all data collection is unified in order to support a) cross study analysis and b) multimodal analysis which is fundamental to the success of PharmaCog.

Scientists will also be supported by the Project Management team (WP9) who will ensure the timely delivery of objectives, while the success of the project will be communicated through the annual dissemination plan developed by the dissemination team (WP10).



Last Updated: Thursday 14 October 2010


  • Acknowledgements

    The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) for the Innovative Medicine Initiative under Grant Agreement No 115009.
  • Innovative Medicines Initiative
  • European Union
  • European Federation of Pharmaceutical Industries and Associations